Quoin Pharmaceuticals, Ltd. (QNRX), Wednesday announced additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome study of QRX003.
The company noted that after six weeks of continued whole body application of QRX003, the subject's skin remains almost completely healed. Moreover, the patient has continued to have no requirement for previously necessary medications such as antibiotics, antivirals, antihistamines and glucocorticoids.
The study also demonstrated that the patient experienced almost complete elimination of pruritus or itch, zero nightly sleep disturbances without any sedating medication, and no adverse events after six weeks.
Following this, the company has received approval to initiate whole body application of QRX003 to a second pediatric Netherton patient. It is expected to commence within a few weeks.
In the pre-market hours, Quoin's stock is surging 94.92 percent, to $0.41 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.